Revelation Biosciences, Inc. Common Stock

REVBNASDAQ • USD
3.50 USD
↘ 0.19 (5.15%)AT CLOSE (03:59 PM EST)
3.84
↗ 0.35 (9.86%)
POST MARKET (AS OF 04:04 PM EST)
Post Market
AS OF 04:04 PM EST
3.84
↗ 0.35 (9.86%)
🔴Market: CLOSED

REVB is currently priced at $3.50. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, REVB appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 20, 2026.

Open?$3.71
High?$3.80
Low?$3.50
Prev. Close?$3.69
Volume?9.8K
Avg. Volume?50.1K
VWAP?$3.72
Rel. Volume?0.20x
Bid / Ask
Bid?$3.51 × 100
Ask?$4.25 × 900
Spread?$0.74
Midpoint?$3.88
Valuation & Ratios
Market Cap?2.0M
Shares Out?683.4K
Float?3.5M
Float %?89.0%
P/E Ratio?N/A
P/B Ratio?0.28
EPS?-$31.35
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Employees
9
Market Cap
2.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-01-11
Address
4660 LAJOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: 650-800-3717
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-11.18Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.36%Low
Short Interest?12.8K
Days to Cover?1.0
Free Float3.5M
Avg Daily Volume39.6K
Settlement Date2026-10-30
Financial Health
Current Ratio?3.98Strong
Quick Ratio?3.98Strong
Cash Ratio?3.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.28CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-246.6%WEAK▾
ROA?
S&P
3
-178.0%WEAK▾
Cash Flow & Enterprise
FCF?$-10211705
Enterprise Value?$-7129924
Fundamentals ratios updated end of day